EMA confirms recommendation to withdraw marketing authorisations for amfepramone medicines

View source ↗

Summary

EMA confirms a recommendation to withdraw marketing authorisations for amfepramone medicines used for weight loss due to safety concerns.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweightness

Drugs mentioned

• amfepramone medicines (amfepramone)